Eunice Hankinson

Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Ben Tran, Tanya Dorff, Madeline Richey, Eunice Hankinson et autres

au, us (code pays fourni par la source)

RWD123 CUSTOMIZATION OF A LARGE LANGUAGE MODEL APPROACH TO CAPTURE PSA AND IMAGING DERIVED REAL-WORLD PROGRESSION EVENTS IN PROSTATE CANCER

Kelly Magee, Patrick Ward, Wanjing Chen, Eunice Hankinson et autres

us (code pays fourni par la source)

Beyond BRCA : Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations.

Eunice Hankinson, Brendan T Kerr, Patrick J. Ward, Khilna Patel et autres

89 Background: Poly(ADP-ribose) polymerase inhibitors (PARPi) are established therapies for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair mutations(m) (HRRm), with the greatest benefit in pts with BRCA mutation ( BRCA m). However, the real-world (rw) distribution of …

us (code pays fourni par la source)

Treatment patterns and survival outcomes among lutetium 177–experienced patients with metastatic castration-resistant prostate cancer.

Ben Tran, Tanya B. Dorff, Madeline Richey, Eunice Hankinson et autres

69 Background: Survival expectations for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving late-line therapies have historically been defined by trials conducted prior to the approval of lutetium-177 vipivotide tetraxetan (Lu177). With Lu177 now established as a standard of care following …

au, us (code pays fourni par la source)

Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (OS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) and frailty or comorbidities.

Enrique Grande, Aristotelis Bamias, Ronald de Wit, Syed A. Hussain et autres

666 Background: Enfortumab vedotin + pembrolizumab (EV+P) is now the preferred 1L tx for la/mUC, showing superior OS vs platinum-based chemotherapy (PBC) in the pivotal EV-302 trial. EV is associated with distinct adverse events, and clinical factors have been proposed to identify …

es, gr, nl, gb, fr, de, us, it, ch (code pays fourni par la source)

A feasibility analysis to align fit-for-purpose real-world (RW) data to emulate the AZUR-1 single-arm clinical trial in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer (RC).

Jeanine M.L. Roodhart, Sean O’Donnell, Linda Kalilani, Eunice Hankinson et autres

70 Background: AZUR-1, a clinical trial (NCT05723562) evaluating dostarlimab for pts with dMMR/MSI-H stage II/III RC, has a single-arm design due to the rarity of dMMR/MSI-H in locally advanced RC, known clinical activity of dostarlimab, 1 and complications of the current multimodal …

nl, us, gb (code pays fourni par la source)

Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): Insights by PTEN status.

Dana E. Rathkopf, Danni Zhao, Jenna M. Collins, Eunice Hankinson et autres

5096 Background: The loss of function of the tumor suppressor gene PTEN is associated with an increased risk of recurrence and poor clinical outcomes in advanced prostate cancer (PC). Current understanding of PTEN prevalence and pt characteristics, treatment patterns, and survival outcomes …

us, gb, ca, jp (code pays fourni par la source)

Assessment of racial/ethnic inequities in uptake of PSMA-PET imaging among patients with metastatic prostate cancer in the United States.

Eunice Hankinson, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett et autres

e13739 Background: Prostate-Specific Membrane Antigen–Positron Emission Tomography (PSMA-PET) imaging has transformed the diagnosis and treatment of prostate cancer (PCa) since 2020 because it can detect smaller PCa lesions earlier than conventional imaging methods. Racial/ethnic inequities in PCa are well documented; yet, little …

us (code pays fourni par la source)

Impact of carboplatin and cisplatin shortages on treatment patterns in patients with metastatic solid tumors.

Emily H. Castellanos, Qianyu Yuan, Niquelle Brown Wadé, Khilna Patel et autres

11149 Background: The United States experienced cisplatin (CP) and carboplatin (CB) shortages in 2023, leading to potential rationing or switching to alternative therapies in multiple cancers. Using a US nationwide, real-world oncology dataset, we assessed changes in the use of CP and …

us (code pays fourni par la source)